We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Physiomics Plc | LSE:PYC | London | Ordinary Share | GB00BDR6W943 | ORD 0.4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.20 | -13.33% | 1.30 | 1.20 | 1.40 | 1.30 | 1.05 | 1.25 | 2,479,405 | 10:28:27 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 597k | -477k | -0.0035 | -3.71 | 1.76M |
Date | Subject | Author | Discuss |
---|---|---|---|
19/6/2020 15:32 | There are no institutional buyers and there never evr has been. Unless you call jc aka ZA an institution | spacedust | |
19/6/2020 15:24 | When the Merck deal happened the reason it went up 30x (and was going to 50x) wasn't just because they did a €500k deal with Merck KGaA. Remember Day 1 it went up about 200-300% Day 2 it went up another 100% Day 3 it went up about 300% before finishing up about up 50% Anyway you get the pucture it took a while for the Market to latch onto what the Contract meant 1. It was validation of PYC technology 2. It represented a step change in Revenues 3. It meant PYC would suddenly be taken more seriously by others ( Customers: Big Pharmas , Small/Medium Bios; Competitors; Partners etc) One thing i didn't appreciate at the time was how far ahead Merck KGaA are. They aren't 'Leading Edge' they are 'Bleeding Edge'. They are so highly regarded in this Immuno-Oncology field other Big Pharma like GSK and PFE Pfizer partner with them. So now if PYC land a Large Pharma similar dynamics and positive feedback loops are initiated. Lots of customers will have more confidence to go with them. Lots of peers may want to partner (Certara/Schrodinger In investor terms Certara/Schrodinger are biggies. They are ultimate most likely acquirers of PYC as a business. PYC clearly aware of industry M&A note recent tweets about $SLP deal and Parexel acquisition of Model Answers. Then on top of all that we may get more Broker coverage and Institutional buyers. That is why i expect 20p+ on a sustained basis | the stigologist | |
19/6/2020 14:34 | Yes please. JC are you on board? It's imperative you are for a sustained rise otherwise goodbye double digits | spacedust | |
19/6/2020 14:26 | Spread tightened, afternoon rally about to commence? ? | aimbagger | |
19/6/2020 13:08 | Fomo and us buying doesn't need to wait until 230pm to start buying our markets are open you numpty dumpty humpty scumpty | spacedust | |
19/6/2020 13:07 | 125k is my buy not a sell | herb clark | |
19/6/2020 12:58 | Cannot buy any as no quote avaialble | carlisle44 | |
19/6/2020 12:39 | Rolaw the thing about days and weeks is that they turn to yrs and in my case decade.....s | spacedust | |
19/6/2020 12:28 | FOMO and US buying to kick in this PM ? | the stigologist | |
19/6/2020 11:47 | We all know news can't be far away. Just a case of a little more patience. I am really hopeful that patience will be rewarded. I have been in here a few years, what's a few more days/weeks/months!! | rolaw1 | |
19/6/2020 11:46 | VAL could be the next one to move like this all IMHO. | 412069 | |
19/6/2020 11:40 | Contract news hasn't even landed yet, anticipation likely to build this afternoon in case it hits on Monday at 7am. | aimbagger | |
19/6/2020 11:12 | Back down to earth. Some Thing leaked Comparitors galore Where are these comments now. Jim the cunning sold out his shares at 8p | spacedust | |
19/6/2020 08:54 | Doc Robinson19 Jun '20 - 06:08 - 5757 of 5762 0 0 0 Will this hit double figures today with or without a RNS ?? Simple answer NO! | chesty1 | |
19/6/2020 08:34 | See if we can crack through 8p today! ? | aimbagger | |
19/6/2020 07:01 | 9.4p today | chicken charlie | |
19/6/2020 06:36 | Doc go back to bed | chicken charlie | |
19/6/2020 06:08 | Will this hit double figures today with or without a RNS ?? | doc robinson | |
19/6/2020 06:08 | An excellent day yesterday.It would be even better to see a share price that reflected the off balance sheet value of the technology which is of course, MULTIPLES of where we are now. It has taken some 20 YEARS to develop and is still well ahead of the curve being world class in every respect. | ant15 | |
18/6/2020 22:42 | I went inside doc browns time machine and got the rns. Some younger peeps scratching their heads thinking who on earth is doc brown | spacedust | |
18/6/2020 22:39 | TIDMPYC Physiomics PLC XX June 2020 Physiomics plc ("Physiomics") or (the "Company") Physiomics awarded further contract Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models and its Virtual Tumour(TM) technology to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce that it has been awarded a further contract of undisclosed value with a large pharmaceutical bio-tech company listed on the Nasdaq exchange. The Project is an extension of the work the Company completed on (currently in a Cancer Research UK-sponsored Phase I/IIa study), which Physiomics announced earlier this year. Physiomics' role is related to the analysis of clinical data from this trial and its work on the initial project was acknowledged in a poster presentation, The Project is expected to be completed in the next six months. Dr Jim Millen, CEO said : "We are delighted to continue to expand our relationship with a key high-profile client. It's also pleasing that we are able to sign new business in the current environment and hope to see this continue over the course of the rest of this calendar year." | spacedust | |
18/6/2020 22:35 | Here is the fifth coming rns | spacedust | |
18/6/2020 20:54 | Your next rns of a new contract will seriously disappoint any new investors new to this company. It will either mention no revenue, or it will be a few thousand. Don't be foolish. | davevt |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions